134 related articles for article (PubMed ID: 27542841)
21. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
23. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53.
Park SH; Park JY; Weiss RH
J Urol; 2008 Jul; 180(1):352-60. PubMed ID: 18499163
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Apoptosis; 2010 Apr; 15(4):412-25. PubMed ID: 19856104
[TBL] [Abstract][Full Text] [Related]
25. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
Ren X; Liu H; Zhang M; Wang M; Ma S
Mol Med Rep; 2016 Sep; 14(3):2431-8. PubMed ID: 27484725
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
28. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
29. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
31. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
[TBL] [Abstract][Full Text] [Related]
32. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
33. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
Peng J; Mo R; Ma J; Fan J
World J Surg Oncol; 2015 May; 13():175. PubMed ID: 25951903
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
35. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H
Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258
[TBL] [Abstract][Full Text] [Related]
36. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.
Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
[TBL] [Abstract][Full Text] [Related]
37. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
Inoue H; Kauffman M; Shacham S; Landesman Y; Yang J; Evans CP; Weiss RH
J Urol; 2013 Jun; 189(6):2317-26. PubMed ID: 23079374
[TBL] [Abstract][Full Text] [Related]
38. Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis.
Huang Y; He P; Ding J
Bioengineered; 2021 Dec; 12(2):12157-12166. PubMed ID: 34781823
[TBL] [Abstract][Full Text] [Related]
39. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
40. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Bender C; Ullrich A
Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
